Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07667322 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT07667322 is a Phase 1 study that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 75 participants.
The verdict
NCT07667322, a Phase 1 study, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS). The study consists of two treatment phases: a dose-escalation and dose-continuation phase. Participants will receive single ascending doses of ocrelizumab SC during an initial dose-escalation phase, with the option to continue treatment with the selected dose of ocrelizumab SC in the dose-continuation phase.
Interventions
- DRUG Ocrelizumab Co-formulated With rHuPH20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2024-12-17 |
| Est. Completion | 2028-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07667322
The ClinicalTrials.gov registry entry for NCT07667322 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ocrelizumab Co-formulated With rHuPH20 is the first listed.
NCT07667322 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07667322 about?
NCT07667322 is a clinical study titled "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis". The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS). The study consists of two treatment phases: a dose-escalation and dose-continuation phase. Participants will receive single as...
What is the current status of trial NCT07667322?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2024-12-17. Estimated completion is 2028-08-01.
What interventions are being tested in trial NCT07667322?
The interventions under investigation include: Ocrelizumab Co-formulated With rHuPH20 (DRUG).
Who is sponsoring clinical trial NCT07667322?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.